US3507866A
(en)
|
1967-08-08 |
1970-04-21 |
Merck & Co Inc |
1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation
|
US3567725A
(en)
|
1968-11-20 |
1971-03-02 |
Merck & Co Inc |
Process for preparation of 1h-imidazo-(4,5-b)pyrazin-2-ones
|
US4317909A
(en)
|
1980-03-24 |
1982-03-02 |
Sterling Drug Inc. |
Preparation of 1,3-dihydro-5-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones
|
US4294836A
(en)
|
1980-03-24 |
1981-10-13 |
Sterling Drug Inc. |
1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]-pyridine-2-thiones and their cardiotonic use
|
US4294837A
(en)
|
1980-03-28 |
1981-10-13 |
Sterling Drug Inc. |
1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]pyridine-2-thiones and their cardiotonic use
|
US4309537A
(en)
|
1980-03-28 |
1982-01-05 |
Sterling Drug Inc. |
Production of imidazo[4,5-b]pyridin-2-ones or thiones
|
GB8709448D0
(en)
|
1987-04-21 |
1987-05-28 |
Pfizer Ltd |
Heterobicyclic quinoline derivatives
|
JPS63275582A
(ja)
|
1987-05-02 |
1988-11-14 |
Naade Kenkyusho:Kk |
2−アミノイミダゾ〔4,5−b〕ピリジン誘導体の製造方法
|
DD262026A1
(de)
|
1987-07-10 |
1988-11-16 |
Akad Wissenschaften Ddr |
Verfahren zur herstellung von 4-substituierten 6-(pyrid-4-yl)-2,4-dihydro-1h-imidazo[4,5-b]pyrid-2-onen
|
FR2643903A1
(fr)
|
1989-03-03 |
1990-09-07 |
Union Pharma Scient Appl |
Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux
|
US4963561A
(en)
|
1990-02-28 |
1990-10-16 |
Sterling Drug Inc. |
Imidazopyridines, their preparation and use
|
TW274550B
(pt)
|
1992-09-26 |
1996-04-21 |
Hoechst Ag |
|
DE19601627A1
(de)
|
1996-01-18 |
1997-07-24 |
Bayer Ag |
Heteroatomhaltige Cyclopentanopyridyl-Oxazolidinone
|
US6031105A
(en)
|
1996-04-09 |
2000-02-29 |
Pfizer Inc |
Substituted pyridines
|
WO1999016438A1
(en)
|
1997-09-26 |
1999-04-08 |
Asta Medica Aktiengesellschaft |
Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function
|
WO1999028459A1
(en)
|
1997-11-27 |
1999-06-10 |
Chugai Research Institute For Molecular Medicine, Inc. |
Examination method, examination reagent and remedy for diseases caused by variation in lkb1 gene
|
ZA9810490B
(en)
|
1997-12-03 |
1999-05-20 |
Dainippon Pharmaceutical Co |
2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
|
EP1186232A4
(en)
|
1999-05-31 |
2004-11-10 |
Chugai Pharmaceutical Co Ltd |
'KNOCKOUT' ANIMALS LACKING THE LKB1 GENE
|
JP2003146987A
(ja)
|
1999-05-31 |
2003-05-21 |
Dainippon Pharmaceut Co Ltd |
2−アリールプリン−9−アセトアミド誘導体
|
JP3814125B2
(ja)
|
1999-06-02 |
2006-08-23 |
大日本住友製薬株式会社 |
2−アリール−8−オキソジヒドロプリン誘導体からなる医薬
|
JP2002100363A
(ja)
|
2000-09-25 |
2002-04-05 |
Mitsubishi Chemicals Corp |
リチウム二次電池用正極材料、リチウム二次電池用正極及びリチウム二次電池
|
JP2002167387A
(ja)
|
2000-11-29 |
2002-06-11 |
Dainippon Pharmaceut Co Ltd |
2−(7,8−ジヒドロ−8−オキソ−9h−プリン−9−イル)酢酸誘導体
|
MXPA03004245A
(es)
|
2000-12-12 |
2003-09-22 |
Neurogen Corp |
Espiro[isobenzofuran-1,4'piperidin]-3-onas y 3h-espiroisobenzofuran-1,4'-piperidinas.
|
WO2002076954A1
(en)
|
2001-03-23 |
2002-10-03 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
RS51012B
(sr)
|
2001-09-04 |
2010-10-31 |
Boehringer Ingelheim Pharma Gmbh. & Co.Kg. |
Novi dihidropteridinoni, postupak za njihovo dobijanje i njihova primena kao lekova
|
JP2005506350A
(ja)
|
2001-10-18 |
2005-03-03 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
サイトカイン阻害薬としての1,4−二置換ベンゾ−縮合尿素化合物
|
PE20030968A1
(es)
|
2002-02-28 |
2004-01-12 |
Novartis Ag |
Derivados de 5-feniltiazol como inhibidores de cinasas
|
US7247621B2
(en)
|
2002-04-30 |
2007-07-24 |
Valeant Research & Development |
Antiviral phosphonate compounds and methods therefor
|
MXPA04010983A
(es)
|
2002-05-06 |
2005-02-14 |
Genelabs Tech Inc |
Derivados de nucleosidos para tratar infecciones por el virus de la hepatitis c.
|
US20040204420A1
(en)
|
2002-08-05 |
2004-10-14 |
Rana Tariq M. |
Compounds for modulating RNA interference
|
EP1556053A4
(en)
|
2002-10-31 |
2006-04-19 |
Amgen Inc |
ANTI-INFLAMMATORY AGENTS
|
AU2003295776B2
(en)
|
2002-11-21 |
2011-05-12 |
Novartis Vaccines And Diagnostics, Inc. |
2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer
|
DE602004021558D1
(de)
|
2003-01-17 |
2009-07-30 |
Warner Lambert Co |
2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
|
EA008778B1
(ru)
|
2003-02-26 |
2007-08-31 |
Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг |
Дигидроптеридиноны, способ их получения и их применение в качестве лекарственных средств
|
GB0305152D0
(en)
|
2003-03-06 |
2003-04-09 |
Novartis Ag |
Organic compounds
|
GB2400101A
(en)
|
2003-03-28 |
2004-10-06 |
Biofocus Discovery Ltd |
Compounds capable of binding to the active site of protein kinases
|
TW200519106A
(en)
|
2003-05-02 |
2005-06-16 |
Novartis Ag |
Organic compounds
|
EP2345661A1
(en)
|
2003-05-30 |
2011-07-20 |
Pharmasset, Inc. |
Modified fluorinated nucleoside analogues
|
JP4705912B2
(ja)
|
2003-06-26 |
2011-06-22 |
メルク・シャープ・エンド・ドーム・コーポレイション |
ベンゾジアゼピンcgrp受容体拮抗物質
|
EP1651673B1
(en)
|
2003-07-17 |
2008-04-16 |
University of Dundee |
Methods for use of an lkb1/strad/mo25 complex
|
GB0320197D0
(en)
|
2003-08-28 |
2003-10-01 |
Novartis Ag |
Organic compounds
|
US20080194019A1
(en)
|
2003-09-09 |
2008-08-14 |
Beth Israel Deaconess Medical Center, Inc. |
Tumor Suppressor Lkb1 Kinase Directly Activates Amp-Activated Kinase
|
JP2008501707A
(ja)
|
2004-06-04 |
2008-01-24 |
アイコス、コーポレーション |
マスト細胞障害を処置するための方法
|
DE102004029784A1
(de)
|
2004-06-21 |
2006-01-05 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
|
WO2006001266A1
(ja)
|
2004-06-23 |
2006-01-05 |
Banyu Pharmaceutical Co., Ltd. |
2-アリールプリン誘導体の製造方法
|
US20060058311A1
(en)
|
2004-08-14 |
2006-03-16 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation
|
GB0420719D0
(en)
|
2004-09-17 |
2004-10-20 |
Addex Pharmaceuticals Sa |
Novel allosteric modulators
|
JP2008514628A
(ja)
|
2004-09-24 |
2008-05-08 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
蛋白質キナーゼ類のイミダゾ{4,5−b}ピラジノン阻害剤
|
GB0423653D0
(en)
|
2004-10-25 |
2004-11-24 |
Piramed Ltd |
Pharmaceutical compounds
|
US7855205B2
(en)
|
2004-10-29 |
2010-12-21 |
Janssen Pharmaceutica Nv |
Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
|
BRPI0517272A
(pt)
|
2004-10-29 |
2008-10-07 |
Tibotec Pharm Ltd |
derivados de pirimidina bicìclicos de inibição de hiv
|
SE0403006D0
(sv)
|
2004-12-09 |
2004-12-09 |
Biovitrum Ab |
New compounds
|
US7767687B2
(en)
|
2004-12-13 |
2010-08-03 |
Biogen Idec Ma Inc. |
Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors
|
WO2006087530A1
(en)
|
2005-02-16 |
2006-08-24 |
Astrazeneca Ab |
Chemical compounds
|
WO2006091737A1
(en)
|
2005-02-24 |
2006-08-31 |
Kemia, Inc. |
Modulators of gsk-3 activity
|
WO2006090169A1
(en)
|
2005-02-25 |
2006-08-31 |
Kudos Pharmaceuticals Limited |
2,4-diamino-pyridopyrimidine derivatives and their use as mtor inhibitors
|
KR20070108916A
(ko)
|
2005-02-25 |
2007-11-13 |
쿠도스 파마슈티칼스 리미티드 |
Mtor 억제제로서 작용하는 하이드라지노메틸,하이드라조노메틸 및 5-원 복소환 화합물 및 이의항암제로서의 용도
|
BRPI0610514A2
(pt)
|
2005-04-05 |
2016-11-16 |
Pharmacopeia Inc |
composto, composição farmacêutica, e, método de tratamento de um distúrbio
|
NZ594628A
(en)
|
2005-10-07 |
2013-04-26 |
Exelixis Inc |
PYRIDOPYRIMIDINONE INHIBITORS OF PI3Ka
|
CA2623768C
(en)
|
2005-10-07 |
2016-04-12 |
Exelixis, Inc. |
N-(3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
|
AU2006302148B2
(en)
|
2005-10-07 |
2012-12-06 |
Exelixis, Inc. |
Pyridopyrimidinone inhibitors of PI3Kalpha
|
EP1946120A2
(en)
|
2005-10-18 |
2008-07-23 |
George Mason Intellectual Properties, Inc. |
Mtor pathway theranostic
|
JP5335432B2
(ja)
|
2005-11-17 |
2013-11-06 |
オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー |
縮合2環系mTOR阻害剤
|
CA2628920C
(en)
|
2005-11-22 |
2015-12-29 |
Kudos Pharmaceuticals Limited |
Pyrido-,pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
|
GB0525080D0
(en)
|
2005-12-09 |
2006-01-18 |
Astrazeneca Ab |
Pyrimidine derivatives
|
GB0525083D0
(en)
|
2005-12-09 |
2006-01-18 |
Astrazeneca Ab |
Pyrimidine derivatives
|
EP1979325A1
(en)
|
2006-01-11 |
2008-10-15 |
AstraZeneca AB |
Morpholino pyrimidine derivatives and their use in therapy
|
US20090281075A1
(en)
|
2006-02-17 |
2009-11-12 |
Pharmacopeia, Inc. |
Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
|
JP5606734B2
(ja)
|
2006-04-25 |
2014-10-15 |
アステックス、セラピューティックス、リミテッド |
医薬化合物
|
AR060631A1
(es)
|
2006-04-26 |
2008-07-02 |
Piramed Ltd |
Derivados de pirimidina y su uso como inhibidores de fosfatidilnositol 3-quinasa (pi3k)
|
JP2009535386A
(ja)
|
2006-05-03 |
2009-10-01 |
アストラゼネカ アクチボラグ |
チアゾール誘導体および抗腫瘍剤としてのその使用
|
US20090118336A1
(en)
|
2006-05-03 |
2009-05-07 |
Laurent David |
Pyrazole derivatives and their use as pi3k inhibitors
|
US20090306126A1
(en)
|
2006-05-22 |
2009-12-10 |
Astrazeneca Ab |
Indole Derivatives
|
PT2583970E
(pt)
|
2006-08-02 |
2016-02-08 |
Cytokinetics Inc |
Certas entidades químicas, composições e métodos compreendendo imidazopirimidinas
|
JP5227321B2
(ja)
|
2006-08-23 |
2013-07-03 |
クドス ファーマシューティカルズ リミテッド |
Mtor阻害剤としての2−メチルモルホリンピリド−、ピラゾ−及びピリミド−ピリミジン誘導体
|
US8268809B2
(en)
|
2006-09-05 |
2012-09-18 |
Emory University |
Kinase inhibitors for preventing or treating pathogen infection and method of use thereof
|
WO2008030744A2
(en)
|
2006-09-05 |
2008-03-13 |
Board Of Regents, The University Of Texas System |
Inhibitors of c-met and uses thereof
|
WO2008032060A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
4-benzimidaz0lyl-6-m0rph0lin0-2-piperazinylpyrimidine derivatives as p13k and mtor inhibitors for the treatment of proliferative disorders
|
WO2008032036A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
6-benzimidaz0lyl-2-m0rph0lin0-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
WO2008032089A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
4-benzimidaz0lyl-2-m0rph0lin0-6-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
WO2008032033A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
WO2008032027A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
Pyrimidine derivatives
|
WO2008032091A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
4-benzimidaz0lyl-6-m0rph0lin0-2-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
WO2008032077A1
(en)
|
2006-09-14 |
2008-03-20 |
Astrazeneca Ab |
Pyrimidine derivatives
|
US20100022534A1
(en)
|
2006-09-14 |
2010-01-28 |
Astrazeneca |
2-benzimidazolyl-6-morpholino-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
EP2057147A1
(en)
|
2006-09-14 |
2009-05-13 |
Astra Zeneca AB |
Pyrimidine derivatives
|
US20090233926A1
(en)
|
2006-09-14 |
2009-09-17 |
Astrazeneca |
2-benzimidazolyl-6-morpholino-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
|
AR063142A1
(es)
|
2006-10-04 |
2008-12-30 |
Pharmacopeia Inc |
Derivados de 2-(bencimidazolil) purina y purinonas 6-sustituidas utiles como inmunosupresores,y composiciones farmaceuticas que los contienen.
|
US7902187B2
(en)
|
2006-10-04 |
2011-03-08 |
Wyeth Llc |
6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
|
NZ576278A
(en)
|
2006-10-19 |
2011-12-22 |
Signal Pharm Llc |
Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
|
EP2078018B1
(en)
|
2006-10-19 |
2012-03-14 |
Signal Pharmaceuticals LLC |
Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
|
CN109970735A
(zh)
|
2006-11-20 |
2019-07-05 |
诺华公司 |
化合物的盐和晶型
|
US20080234262A1
(en)
|
2007-03-21 |
2008-09-25 |
Wyeth |
Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
|
UA99284C2
(ru)
|
2007-05-11 |
2012-08-10 |
Елі Ліллі Енд Компані |
ИНГИБИТОРЫ р70 S6-КИНАЗЫ
|
CN101801963A
(zh)
|
2007-07-09 |
2010-08-11 |
阿斯利康(瑞典)有限公司 |
用于治疗增殖性疾病的三取代的嘧啶衍生物
|
AR067478A1
(es)
|
2007-07-09 |
2009-10-14 |
Astrazeneca Ab |
Compuestos derivados de morfolina pirimidina
|
EA018708B1
(ru)
|
2007-07-09 |
2013-10-30 |
Астразенека Аб |
ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
|
MX2010004260A
(es)
|
2007-10-16 |
2010-04-30 |
Wyeth Llc |
Compuestos de tienopirimidina y pirazolopirimidina y su uso como inhibidores de mtor cinasa y pi3 cinasa.
|
WO2009086303A2
(en)
|
2007-12-21 |
2009-07-09 |
University Of Rochester |
Method for altering the lifespan of eukaryotic organisms
|
CN102014914A
(zh)
|
2008-01-15 |
2011-04-13 |
惠氏有限责任公司 |
3h-[1,2,3]三唑并[4,5-d]嘧啶化合物、其作为mtor激酶和pi3激酶抑制剂的用途、以及它们的合成
|
WO2009102986A1
(en)
|
2008-02-15 |
2009-08-20 |
Catholic Healthcare West (D/B/A St. Joseph's Hospital And Medical Center) |
Treatment of adenocarcinoma expressing lkb1 with mtor inhibitor in combination with cox1 inhibitor
|
WO2010006072A2
(en)
|
2008-07-08 |
2010-01-14 |
The Regents Of The University Of California |
Mtor modulators and uses thereof
|
US8110578B2
(en)
*
|
2008-10-27 |
2012-02-07 |
Signal Pharmaceuticals, Llc |
Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
|
AU2009324894B2
(en)
|
2008-11-25 |
2015-04-09 |
University Of Rochester |
MLK inhibitors and methods of use
|
ES2661850T3
(es)
|
2009-09-14 |
2018-04-04 |
Gilead Sciences, Inc. |
Moduladores de receptores del tipo toll
|
EP3091021B1
(en)
*
|
2009-10-26 |
2019-08-28 |
Signal Pharmaceuticals, LLC |
Methods of synthesis and purification of heteroaryl compounds
|
AU2010336509A1
(en)
|
2009-12-23 |
2012-07-19 |
Elan Pharmaceuticals, Inc |
Pteridinones as inhibitors of polo-like kinase
|
BR112012019459A2
(pt)
|
2010-02-03 |
2017-10-17 |
Signal Pharm Llc |
identificação de mutação de lkb1 como um biomarcador preditivo para sensibilidade para inibidores de tor quinase.
|
US20110318336A1
(en)
|
2010-03-29 |
2011-12-29 |
George Mason Intellectual Properties, Inc. |
Identification and Treatment of Aggressive Lung Cancer Tumors
|
US20120028972A1
(en)
|
2010-07-30 |
2012-02-02 |
Lilly Wong |
Biomarker assays for detecting or measuring inhibition of tor kinase activity
|
AU2012290056B2
(en)
|
2011-08-03 |
2015-03-19 |
Signal Pharmaceuticals, Llc |
Identification of gene expression profile as a predictive biomarker for LKB1 status
|
TWI708605B
(zh)
*
|
2011-10-19 |
2020-11-01 |
標誌製藥公司 |
以tor激酶抑制劑治療癌症
|
EA026390B1
(ru)
|
2011-12-02 |
2017-04-28 |
СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи |
ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ 7-(6-(2-ГИДРОКСИПРОПАН-2-ИЛ)ПИРИДИН-3-ИЛ)-1-((ТРАНС)-4-МЕТОКСИЦИКЛОГЕКСИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1Н)-ОНА, ИХ ТВЕРДЫЕ ФОРМЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
EP2817029B1
(en)
|
2012-02-24 |
2019-07-10 |
Signal Pharmaceuticals, LLC |
Methods for treating non-small cell lung cancer using tor kinase inhibitor combination therapy
|
BR112014022703A2
(pt)
|
2012-03-15 |
2021-05-04 |
Signal Pharmaceuticals, Llc |
método para o tratamento de carcinoma de células escamosas de cabeça e de pescoço, método para melhorar os critérios de avaliação, método para inibição da fosforilação, método para inibição de dna, método para a medição da inibição da fosforilação, kit
|
EP2825169B1
(en)
|
2012-03-15 |
2018-05-09 |
Signal Pharmaceuticals, LLC |
Treatment of cancer with tor kinase inhibitors
|
BR112014022697A2
(pt)
|
2012-03-15 |
2020-06-30 |
Signal Pharmaceuticals, Llc |
Uso de uma quantidade eficaz de um inibidor de quinase tor,método para melhorar o critério de avaliação de resposta,método para a inibição da fosforilação, método para a inibiçãoda atividade da proteína, método para a medição da inibição dafosforilação, kit
|
UA114194C2
(uk)
|
2012-03-15 |
2017-05-10 |
Сігнал Фармасьютікалз, Елелсі |
Лікування раку інгібітором тоr кінази
|
AU2013203714B2
(en)
|
2012-10-18 |
2015-12-03 |
Signal Pharmaceuticals, Llc |
Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
|
EP2986321A1
(en)
|
2013-04-17 |
2016-02-24 |
Signal Pharmaceuticals, LLC |
Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
|
AU2014253978B2
(en)
|
2013-04-17 |
2019-06-06 |
Signal Pharmaceuticals, Llc |
Combination therapy comprising a TOR kinase inhibitor and a 5-Substituted Quinazolinone Compound for treating cancer
|
MX2015014455A
(es)
|
2013-04-17 |
2016-07-21 |
Signal Pharm Llc |
Terapia de combinacion que comprende un inhibidor de tor cinasa y n-(3-(5-fluoro-2-(4-(2-metoxietoxi)fenilamino)pirimidin-4-ilamino )fenil)acrilamida para tratar cancer.
|
NZ629230A
(en)
|
2013-04-17 |
2017-05-26 |
Signal Pharm Llc |
Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
|
JP6389241B2
(ja)
|
2013-04-17 |
2018-09-12 |
シグナル ファーマシューティカルズ,エルエルシー |
癌を治療するためのTORキナーゼ阻害剤及びIMiD化合物を含む組合せ療法
|
CA2908957C
(en)
|
2013-04-17 |
2021-05-18 |
Signal Pharmaceuticals, Llc |
Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
|
CA2908830C
(en)
|
2013-04-17 |
2021-12-07 |
Signal Pharmaceuticals, Llc |
Treatment of cancer with dihydropyrazino-pyrazines
|
EP2986297A1
(en)
|
2013-04-17 |
2016-02-24 |
Signal Pharmaceuticals, LLC |
Treatment of cancer with dihydropyrazino-pyrazines
|